Your browser doesn't support javascript.
loading
Combined Effect of Anti-SSEA4 and Anti-Globo H Antibodies on Breast Cancer Cells.
Lee, Ruey-Herng; Wang, Yu-Jen; Lai, Ting-Yen; Hsu, Tsui-Ling; Chuang, Po-Kai; Wu, Han-Chung; Wong, Chi-Huey.
Affiliation
  • Lee RH; Genomics Research Center, Academia Sinica, Taipei 115, Taiwan.
  • Wang YJ; Department of Chemistry, National Taiwan University, Taipei 106, Taiwan.
  • Lai TY; Genomics Research Center, Academia Sinica, Taipei 115, Taiwan.
  • Hsu TL; Institute of Biochemical Sciences, National Taiwan University, Taipei 106, Taiwan.
  • Chuang PK; Genomics Research Center, Academia Sinica, Taipei 115, Taiwan.
  • Wu HC; Genomics Research Center, Academia Sinica, Taipei 115, Taiwan.
  • Wong CH; Department of Chemistry, The Scripps Research Institute, La Jolla, California 92037, United States.
ACS Chem Biol ; 16(8): 1526-1537, 2021 08 20.
Article in En | MEDLINE | ID: mdl-34369155
ABSTRACT
The globo-series glycosphingolipids (SSEA3, SSEA4, and Globo H) were shown to express in many cancers selectively, and a combination of anti-SSEA4 and anti-Globo H antibodies was able to suppress tumor growth in mice inoculated with breast cancer cell lines. To further understand the effect, we focused on the combined effect of the two antibodies in target binding and antibody-dependent cellular cytotoxicity (ADCC) in vitro. Here, we report that the binding of anti-Globo H antibody (VK9) to MDA-MB231 breast cancer cells was influenced by anti-SSEA4 antibody (MC813-70), and a combination of both antibodies induced a similar effect as did anti-SSEA4 antibodies alone in a reporter-based ADCC assay, indicating that SSEA4 is a major target in breast cancer due to its higher expression than Globo H. Furthermore, we showed that a homogeneous anti-SSEA4 antibody (chMC813-70-SCT) designed to maximize the ADCC activity can be used to isolate a subpopulation of natural killer (NK) cells that exhibit an ∼23% increase in killing the target cells as compared to the unseparated NK cells. These findings can be used to predict a therapy outcome based on the expression levels of antigens and evaluate therapeutic antibody development.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antigens, Tumor-Associated, Carbohydrate / Stage-Specific Embryonic Antigens / Antibodies Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: ACS Chem Biol Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antigens, Tumor-Associated, Carbohydrate / Stage-Specific Embryonic Antigens / Antibodies Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: ACS Chem Biol Year: 2021 Document type: Article